ViewRay MRIdian Clinical Experience to be highlighted by Five Leading Centers at Largest Radiation Oncology Meeting

MRIdian Linac Technology featured in Scientific Sessions

News provided by

Sep 22, 2016, 08:30 ET

CLEVELAND, Sept. 22, 2016 /PRNewswire/ --ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that the company's MRIdian System and MRIdian Linac technology will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), to be held September 25-28, 2016 in Boston.

MRI-guided radiation therapy continues to be a topic of significant interest, as reflected by the 18 MRIdian clinical presentations and posters accepted as part of ASTRO's Scientific Sessions. These presentations will be given by MRIdian users from Washington University and Siteman Cancer Center at Barnes-Jewish Hospital (Washington University); University of California, Los Angeles Health System and Jonsson Comprehensive Cancer Center (UCLA); and The University of Wisconsin Carbone Cancer Center (University of Wisconsin).

Eleven of the Scientific Session presentations will focus on MRIdian's adaptive capabilities, which enable clinicians to adapt treatment in real-time to changes and movement in a patient's anatomy, providing truly personalized medicine. ViewRay's integrated software designed for real-time treatment adaptation has enabled more than 600 on-table adaptive treatments to date. Other Scientific Session presentations will cover MRIdian benefits across a number of clinical indications including lymphoma, head and neck, abdominal, bladder, breast, gastric, pancreatic and prostate cancers.

MRIdian Linac technology will also be highlighted at the conference as part of ASTRO's Scientific Sessions. Researchers from Washington University will highlight a presentation titled "The design and implementation of a novel compact linac-based MRI guided radiation therapy (MR-IGRT) system" and researchers from UCLA will highlight a presentation titled, "The physics of a novel compact linear accelerator–based magnetic resonance imaging–guided radiation therapy system."

Earlier this week, ViewRay announced that the company had received CE Mark approval for the MRIdian Linac and had submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its MRIdian Linac technology. MRIdian Linac is available for sale and clinical use in Europe; however, in the United States, the technology is available for non-clinical research use only at this time.

"This is an exciting ASTRO for ViewRay, having recently received Japanese and Chinese regulatory approval for MRIdian, secured CE Mark approval for MRIdian Linac, and submitted our 510(k) application for the MRIdian Linac technology to the FDA," said Chris A. Raanes, president and chief executive officer of ViewRay. "We now look forward to presentations featuring MRIdian clinical experience and MRIdian Linac technology research by leading institutions at ASTRO."

Visitors to ViewRay's booth #12001 can hear first-hand clinical experience from Washington University; UCLA; University of Wisconsin; and VU University Medical Center (VUmc), Amsterdam. These presentations will take place at various times from Sunday, September 25 through Tuesday, September 27.

ViewRay will also host one of ASTRO's Industry Expert Theater sessions, titled "Implementation of an MRI-Guided Radiation Therapy Program: Experience from the U.S. and Abroad," which will take place on Tuesday, September 27 at 11:45 a.m. in Hall A, Theater 2. This session will feature presentations by Frank Lagerwaard, M.D., from VUmc, and Lorraine Portelance, M.D. from the University of Miami, Sylvester Comprehensive Cancer Center.

A full list of MRIdian-focused ASTRO Scientific Session presentations and in-booth talks is available at http://www.viewray.com/ASTRO_2016.htm.

About ViewRay

ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc. The MRIdian Linac is a technology under development and is not available for sale or distribution in the United States.

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the presentations to be featured at ASTRO. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.

SOURCE ViewRay, Inc.